Literature DB >> 35368815

Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO.

Roger A Rodby1.   

Abstract

Entities:  

Keywords:  CKD 4/5; chronic kidney disease; gadolinium; nephrogenic systemic fibrosis

Mesh：

Substances：

Year:  2020        PMID： 35368815      PMCID： PMC8785746          DOI： 10.34067/KID.0005792020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  14 in total

1.  Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?

Authors:  Diego R Martin
Journal:  Am J Kidney Dis       Date:  2010-09       Impact factor: 8.860

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

Review 3.  Risk factors for NSF: a literature review.

Authors:  Martin R Prince; Hong Lei Zhang; Giles H Roditi; Tim Leiner; Walter Kucharczyk
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

4.  Virtual Elimination of Nephrogenic Systemic Fibrosis: A Medical Success Story with a Small Asterisk.

Authors:  Matthew S Davenport
Journal:  Radiology       Date:  2019-07-02       Impact factor: 11.105

5.  Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors:  Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

6.  A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.

Authors:  Hanieh Attari; Yan Cao; Tina R Elmholdt; Yize Zhao; Martin R Prince
Journal:  Radiology       Date:  2019-07-02       Impact factor: 11.105

Review 7.  Gadolinium use in patients with kidney disease: a cause for concern.

Authors:  Mark A Perazella; Roger A Rodby
Journal:  Semin Dial       Date:  2007 May-Jun       Impact factor: 3.455

8.  Incidence of nephrogenic systemic fibrosis at two large medical centers.

Authors:  Martin R Prince; Honglei Zhang; Michael Morris; Jennifer L MacGregor; Marc E Grossman; Jeffrey Silberzweig; Robert L DeLapaz; Henry J Lee; Cynthia M Magro; Anthony M Valeri
Journal:  Radiology       Date:  2008-09       Impact factor: 11.105

9.  Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.

Authors:  Thomas Lauenstein; Francisco Ramirez-Garrido; Young Hoon Kim; Sung Eun Rha; Jens Ricke; Sith Phongkitkarun; Joachim Boettcher; Rajan T Gupta; Pornpim Korpraphong; Wiwatana Tanomkiat; Julia Furtner; Peter S Liu; Maren Henry; Jan Endrikat
Journal:  Invest Radiol       Date:  2015-06       Impact factor: 6.016

10.  A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.

Authors:  Sadichhya Lohani; Jon Golenbiewski; Abhishek Swami; Alexandra Halalau
Journal:  BMJ Case Rep       Date:  2017-10-11
View more
  1 in total

1.  Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY.

Authors:  Ali K Abu-Alfa
Journal:  Kidney360       Date:  2020-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.